🇺🇸United States·April 01, 2026·daily

US Corporate Distress Financial Stress SEC Filings — April 01, 2026

Across 44 8-K filings in the USA Corporate Distress & Bankruptcy stream (28 new), the dominant theme is proactive liquidity enhancement via 22+ credit facility amendments, extensions, or increases (e.g., Primo Brands refin $3.09B, American Assets Trust rev to $500M), signaling lender confidence and low imminent distress despite the stream focus. No outright bankruptcies or going concern warnings; mild distress in TBHC Nasdaq MVPHS deficiency (delist risk Sept 2026) and Westwater's SK On contract termination. Positive capital allocation trends include consistent dividends (Armour $0.24/share Apr, Nuveen $0.170/share Apr 28) and equity raises/mergers (SharonAI $1.25BN TCV, Cyclerion/Korsana). Period trends sparse but highlight modest fund returns (Nuveen Churchill Class I: 0.21% 1-mo, 0.74% YTD as of Feb 2026) vs stable REIT payouts; no broad YoY/QoQ declines. Forward catalysts cluster in Q2-Q3 2026 (merger closes, production ramps). Portfolio implication: Sector resilient, favoring liquidity plays over distress shorts; monitor delist/termination outliers for alpha.

44 high priority44 total filings

🇺🇸United States·April 01, 2026·daily

US Executive Officer Management Changes SEC — April 01, 2026

Across 34 filings in the USA Executive & Director Changes stream (22 new since last brief), the dominant theme is aggressive leadership refreshes with 18 new appointments (8 CFOs/COOs, 10+ directors) versus 9 departures/resignations, emphasizing experienced hires in finance, tech/AI, and biopharma to drive 2026 growth amid M&A integrations and strategic pivots. Positive sentiment prevails in 16/34 (47%) filings, driven by hires like Zymeworks' Royalty Pharma CFO and Nexscient's AI CTO acquisition, while neutral/mixed in departures with reaffirmed FY2026 guidance (CVGI, Avantor, Clover). No broad period-over-period financial declines noted, but forward-looking highlights include Bunge's $Viterra synergy PBRSUs (2026-2028), Predictive Oncology's $7.5M 2026 run-rate income est from $12M AI GPU deals, and Associated Banc's post-merger 2025 record net income. Capital allocation trends favor equity incentives (e.g., Consensus Cloud $700K+ grants vesting on 2026 metrics, EPAM $3M RSU retention), signaling alignment without dividends/buybacks mentioned. Portfolio-level pattern: Small/mid-cap turnover (avg materiality 7/10) with interim stability suggests operational continuity, but NovaBay's pharma-to-Stablecoin pivot (materiality 9/10) flags high-risk reinvention. Implications: Bullish for growth-oriented firms, watch CFO interims for execution risks in H1 2026.

34 high priority34 total filings

🇺🇸United States·April 01, 2026·daily

US Corporate Board Director Changes SEC Filings — April 01, 2026

Across 34 filings from April 1, 2026, a surge in C-suite leadership changes dominates, with 9 CFO-related shifts (5 appointments, 3 departures/terminations, 1 interim promotion) signaling high turnover amid growth strategies in tech, biotech, and finance sectors. Board appointments (14 positive/neutral additions) emphasize expertise in finance, M&A, and AI, often tied to post-acquisition integrations (e.g., Bunge Viterra synergies 2026-2028, Associated Banc-Corp merger Q3 2026 conversion). Positive sentiment prevails in 16/34 filings (47%), driven by hires like Royalty Pharma alum at Zymeworks and Goldman Sachs vet at Elauwit, while neutral/mixed in resignations and equity grants. No broad YoY revenue declines noted, but reaffirmations of FY2026 guidance in 5 companies (CVGI, Avantor, Clover Health) despite changes indicate operational stability; equity incentives average $300K-$3M grants vesting 3-4 years on performance metrics. Portfolio trend: 65% of changes post-2025 M&A/IPO, with compensation up 20-50% YoY for new execs (e.g., Consensus CFO base $345K). Implications: Bullish for strategic refreshes in AI/biotech, caution on CFO churn potentially disrupting Q2 2026 reporting.

34 high priority34 total filings

🇺🇸United States·April 01, 2026·daily

US Merger & Acquisition SEC Filings — April 01, 2026

A surge in US M&A and takeover activity dominates the 30 filings, with 12 bank/regional financial mergers completing on April 1, 2026 (e.g., CWBC/UBFO at $185.5M, SPFI/BOH adding $744M assets, FirstSun/First Foundation creating $20.4B asset entity), signaling aggressive consolidation in regional banking amid $5B-$34B combined asset footprints. SPAC ecosystem thrives with 6 IPO pricings/LOIs (e.g., Future Money $100M, QDRO $200M) and preparatory restructurings, while divestitures (8 cases) boost pro forma cash (e.g., Duke $2.48B proceeds, CHS $459M gain) but compress revenues (avg -15% YoY pro forma across 7 with data). Spin-offs like Versigent (Aptiv carve-out, $8.8B rev +3% YoY, EBITDA to expand 200bps over 3yrs) and mixed JV/deals (Lands' End $300M IP swap) highlight portfolio optimization. Portfolio-level trends show pro forma net income gains from one-time sale gains (avg +100% in 5 cases) offsetting op rev declines (-1.8% to -55%), with positive sentiment in 70% of filings. Implications: Regional banks gain scale for efficiency; watch summer 2026 systems conversions as catalysts; SPACs signal dry powder for de-SPAC waves.

30 high priority30 total filings

🇺🇸United States·April 01, 2026·monthly

US Pre-Market SEC Filings Roundup — April 01, 2026

Across 50 overnight SEC filings (March 31-April 1, 2026), mixed sentiment prevails with 18 mixed, 9 positive, 8 negative, and rest neutral, driven by volatile period-over-period trends: revenue declines averaging -30% YoY in agribusiness (e.g., Cal-Maine -53%, OLB Group -32%) offset by growth in consumer/luxury (RH +8.1%, Charlie's +169%) and select industrials (ASE Tech +8.4%). SPAC/de-SPAC activity surges with 7 filings (Haymaker, Golden Entertainment approvals, Brag House amendments), signaling merger momentum amid $167M+ PIPE raises. Capital allocation leans shareholder-friendly: dividends declared (Weyerhaeuser +5% to $0.21, Cal-Maine $0.36, Global Net Lease $0.19), buybacks (News Corp $1B program, Cal-Maine $24.3M), but cash burn persists in biotechs/small caps. Outliers include RH's net income +72% YoY and Maui Land's leasing +33% YoY, while impairments/goodwill write-offs hit 8 firms (e.g., LFTD $23M). Forward catalysts cluster in April-May (meetings, dividends, acquisitions), implying pre-market volatility in SPACs, foods, and REITs. Portfolio implication: Rotate from cyclical agri declines to SPAC completions and dividend growers for alpha.

31 high priority19 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Technology Sector SEC Filings — March 31, 2026

Across 29 diverse SEC filings (primarily small/mid-cap non-tech firms despite S&P 500 Tech stream focus, with Snowflake and SEALSQ as key tech outliers), overarching themes include volatile revenue growth (12/29 firms reported YoY revenue increases averaging +200% in winners like Adia Nutrition +10,885%, but 8/29 declines averaging -25% like Planet Green -35%), persistent net losses widening in 14/29 (avg +50% YoY), offset by positive capital allocation in 5/29 (buybacks, dividends). Margin trends mixed: compression in 7/29 (e.g., BlockchAIn 19% vs prior 37%), improvements in cinema/real estate niches. Critical developments: M&A/mergers (Richmond Mutual, Reading acquisitions), biotech catalysts (Immunic/Imunon Phase 3 data E2026), financing wins (ImmunityBio $75M non-dilutive), but red flags in dilution/negative equity (11/29). Portfolio implications: Favor capital return plays and turnaround bios over loss-making microcaps; tech signals limited but Snowflake guidance reaffirm stable. Sector patterns signal caution on expense surges outpacing sales in growth firms.

18 high priority11 medium29 total filings

🇺🇸United States·March 31, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 31, 2026

Across 35 NASDAQ-100 related SEC filings from March 31, 2026, mixed sentiment dominates (14/35 filings), reflecting narrowed losses in 8 companies (e.g., Reading International -60% YoY net loss improvement, Aqua Metals -8%) amid revenue declines in 7 (avg -5% YoY, led by Intelligent Group -9%). Strong outliers include Commercial Metals +21.6% YoY Q2 sales to $2.13B and Adia Nutrition +10,885% YoY revenue to $700k, while biotech firms like Imunon and ImmunityBio show cost cuts (-23%) and non-dilutive funding ($75M). Capital allocation trends favor returns with 3 buyback/dividend announcements (First Northern 6% shares, Camden $0.42/share), debt reductions (Reading -$32M), and M&A (Richmond Mutual $85M deal). SPACs face heavy redemptions and going concern doubts (Welsbach, Jaws Mustang, Metal Sky), signaling portfolio risks in speculative vehicles. Forward catalysts cluster in May 2026 shareholder votes and biotech data (Immunic Phase 3 end-2026), implying alpha in bancorps/turnarounds but caution on metals/mining impairments. Overall, portfolio-level trends show improving profitability (6/12 annual reports with narrower losses) but rising debt (Commercial Metals doubled LT debt post-acquisition) and dilution (Aditxt shares +113%).

21 high priority14 medium35 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Financials Sector SEC Filings — March 31, 2026

Across 50 filings from diverse sectors mislabeled under 'USA S&P 500 Financials' (primarily biotechs, SPACs, tech, and limited true financials like insurers/REITs), mixed sentiment dominates (24/50 mixed), with 12 reporting revenue declines averaging -25% YoY (e.g., Beyond Meat -15.6%, Investview -31%, Co-Diagnostics -84%), offset by cost reductions in 15 firms (avg op ex down 30-50%, e.g., BioAtla R&D -31% YoY). Margin compression prevalent in 8/15 with metrics (avg gross margin -500bps, e.g., Beyond Meat -1000bps FY), but net losses improved in 10 cases via one-offs/gains (e.g., AIRO EBITDA positive turn). M&A surges as lifeline: Centessa/Lilly $6.3B (40% premium, Q3 2026 close), Coursera/Udemy merger (April 9 meetings), Sun Country/Allegiant. True financials stable: Lincoln National $2B credit to 2031, Ashford Hospitality $580M refinance/debt elimination, Old Republic proxy routine. Forward catalysts cluster Q2-Q3 2026 (mergers, approvals, AGMs May), signaling alpha in M&A arb/distressed biotechs amid liquidity crunches (18 firms cash <1yr runway). Portfolio implication: overweight M&A targets, avoid persistent loss-makers without catalysts.

35 high priority15 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 31, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (despite diverse inclusions like CMBS trusts and non-staples), dominant themes are routine CMBS 10-K compliance reports (28/50 filings) affirming servicer adherence with widespread master servicer transitions from Wells Fargo to Trimont LLC effective March 1, 2025, signaling operational stability but no financial upside. Operating companies show mixed period trends: revenue flat/declining in 7/10 with financials (e.g., KORE flat YoY, Movano -57% YoY, Hughes -8% YoY), but loss narrowing in KORE (-57% YoY net loss), BrainStorm (-11% YoY), and Movano (-23% YoY); margin compression in South Dakota Soybean (-40 bps) and Proficient Auto (EBITDA margin -590 bps). Capital allocation highlights Marsh & McLennan $2B record buybacks +10% dividends and SmartStop $1.60 annualized dividend target. Forward catalysts include KORE $726M merger (Q2/Q3 2026), BrainStorm Phase 3b enrollment (~200 pts), and Constellation earnings outlook call. Portfolio-level: 80% neutral sentiment in trusts, mixed in ops cos; no insider trades noted, low M&A in staples core but supply chain stress evident.

43 high priority7 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Industrials Sector SEC Filings — March 31, 2026

Across 50 filings in the USA S&P 500 Industrials stream (broadly encompassing industrials-adjacent sectors like defense, energy services, and construction-related CMBS), a dominant theme is routine compliance in 20+ CMBS 10-Ks with widespread master servicer transitions from Wells Fargo to Trimont LLC effective March 1, 2025, signaling operational stability in commercial real estate financing. Period-over-period trends show mixed financials: revenue growth in 8/15 operating companies averaging +20% YoY (e.g., Dawson Geophysical +16%, Range Resources +11%), but persistent net losses or NAV declines in 7 cases (avg -20% equity/NAV drop); Adjusted EBITDA surges in turnarounds like TruBridge (+51% Patient Care) and Dawson (+139%). Positive M&A and capital allocation stand out, with Red Cat's drone acquisitions ($25M+ earnout), Oramed's asset sale with revenue sharing, Range Resources' $231M buybacks/$86M dividends, and First Northern's 6% share repurchase program (~$15.6M). Biotech/industrials crossovers like Tonix (Lyme Ph1 success) and Telomir (TNBC IND) add forward catalysts, while risks include Lipella bankruptcy and going concern doubts in EMAT. Portfolio-level, 65% neutral/positive sentiment, with cap alloc favoring returns over reinvestment; implications favor selective longs in defense/energy services amid stable RE backdrop.

39 high priority11 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Energy Sector SEC Filings — March 31, 2026

Across 12 filings in the USA S&P 500 Energy intelligence stream, a dominant theme is revenue contraction averaging -25% YoY in 7/10 reporting 10-Ks (e.g., Hughes -8%, Nocopi -29%, Zapata -100%), offset by aggressive opex reductions narrowing net losses in 6/9 loss-making firms (e.g., Nocopi -94% loss improvement, Magellan -44%). Halliburton stands out with resilient $2.9B operating cash flow and $1.6B shareholder returns (85% of FCF) despite -3% revenue, signaling sector strength in services amid North America weakness (-6%). Impairments and one-offs drove volatility (Hughes $1.4B charges), while small caps like Lion Copper flipped to $4.4M net income via deconsolidation gains. Capital allocation leans defensive with buybacks/dividends in Halliburton, contrasted by equity raises and debt issuance (Exxon $169M notes). Portfolio-level trends show margin resilience via cost cuts but cash burn persists in explorers (Lion -70% cash drop), raising liquidity risks. Upcoming catalysts include Halliburton AGM (May 20, 2026) and Howard Hughes acquisition close (Q2 2026), with mixed sentiment (7/12 mixed/negative) implying cautious positioning amid energy transition pressures.

8 high priority4 medium12 total filings

🇺🇸United States·March 31, 2026·daily

US Material Events SEC 8-K Filings — March 31, 2026

Across 50 8-K filings from March 2026, dominant themes include a surge in M&A transactions (10+ deals like Repay-KUBRA, SCYNEXIS-SCY-770, Red Cat-Quaze), debt refinancings/extensions (Alerus, Prologis, Ares, Lincoln National), and widespread executive changes/appointments (20+ instances, notably Jay Jacobs replacing Shannon Ghia across 8 BlackRock iShares ETF sponsors). Period-over-period trends show revenue growth in standout performers like nCino (+10% FY2026 YoY to $594.8M, first GAAP profit) and T1 Energy (record Q4 production 1.13GW YoY, FY 2.79GW in-line), but persistent losses (T1 Q4 net loss $190M improved from $367M). Forward-looking catalysts cluster in Q2 2026 (merger closings, M&A approvals), with positive guidance in payments/energy/biotech offsetting bankruptcy (Lipella) and wind-downs (Allbirds). Portfolio-level patterns reveal financials/real estate leaning toward neutral refinancing for stability, while biotech/tech exhibit bullish expansion via tuck-ins and equity raises. Capital allocation favors M&A reinvestment over dividends/buybacks, signaling growth conviction amid mixed sentiment (25% positive, 10% negative). Actionable implications: overweight fintech/biotech M&A plays, monitor ETF sponsor stability, avoid distressed pharma.

50 high priority50 total filings

🇺🇸United States·March 31, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 31, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily small-cap and micro-cap names with DJ30 exposure themes), overarching patterns reveal mixed financial performance with 12/20 10-Ks showing revenue declines averaging -15% YoY (e.g., Investview -31%, Nuvve -9.3%), offset by loss improvements in 8/20 cases via cost cuts (e.g., Innovative Payment G&A -46%). Capital raises via PIPEs, preferred stock, and SPAC mergers dominate (e.g., Predictive $343.5M PIPE, Trailblazer SPAC close), alongside M&A activity in defense/tech (Red Cat acquisitions) and airlines (Sun Country merger). Forward-looking catalysts include Keenova's 2026 sales guidance $1.94-2B (+YoY growth) and trial readouts Q2-Q4 2026, while risks cluster around going concerns (VivoSim, Welsbach), dilutions, and impairments. Portfolio-level trends show margin pressures in 7/15 ops-focused firms (avg gross margin -100bps), but improving free cash flow in telco/IoT (KORE +$12.4M YoY). Bullish signals from buybacks (First Northern 6% shares) and distributions (AGL $0.60/share); bearish from Nasdaq delist risks (American Rebel). Implications: Selective opportunities in M&A catalysts and turnarounds amid broad volatility.

33 high priority17 medium50 total filings

🇺🇸United States·March 31, 2026·daily

US SEC Filings Daily Market Digest — March 31, 2026

Across 50 SEC filings from March 31, 2026, dominant themes include mixed financial results with revenue growth in energy (e.g., Dawson Geophysical Q4 fee revenue +67% YoY) offset by widening losses in biotech (OS Therapies net loss +224% YoY) and crypto (Solana FY net loss -$40.9M widened from -$11.7M), alongside aggressive financing via credit facilities (Prologis, Ares), ATM offerings (Satellogic $50M), and debt issuances (Ellington $50M notes). Capital allocation leans bullish with buybacks (First Northern 6% shares ~$15.6M, Solana $3.4M, News Corp $1B program) and dividends (AGL $0.60/share, SmartStop $0.1315/month), signaling management confidence amid stable mortgage trust servicer transitions. Biotech and energy show forward catalysts like Aktis Oncology Phase 1b trials mid-2026 and AleAnna's Gradizza Concession growth, while SPACs (Berto, Invest Green) hold strong trust assets but face combination deadlines. Portfolio-level trends reveal 8/15 energy/oil firms with production/revenue volatility (avg +20% gas but -10% oil YoY), margin stability in services (Dawson flat 21%), and cash burn in high-growth areas (DiaMedica $29.1M operating cash use). M&A activity (Red Cat $25M Quaze + $5M earnout, Range Impact coal mines) highlights defense/mining expansion, with relative outperformance in Adjusted EBITDA (KORE +19% FY, Dawson +139%). Overall, actionable intelligence favors monitoring capital returns and catalysts over deteriorating biotechs.

33 high priority17 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 31, 2026

Across 50 filings from the USA S&P 500 Consumer Discretionary intelligence stream (primarily hotels, retail, though broadened to related filings), mixed sentiment dominates (20/50 filings), with 2025 FY results revealing average revenue growth of ~7% YoY in key operators like Ross Stores (+8%), Check Point (+6.3%), TruBridge (+1%), and Proficient Auto (+78.7%), but widespread margin compression averaging -100bps (e.g., Ross -30bps to 11.9%, Check Point op margin -5.1%) due to rising expenses (R&D +15.7% at Check Point, SG&A +200bps at Ross). Liquidity concerns persist in smaller caps (ENDRA cash $762k, FinTrade net loss +332%), offset by capital allocation strength including buybacks (First Northern 6% shares ~$15.6M, Marsh & McLennan $2B), dividends (SmartStop $1.60 annualized, AGL $0.60/share), and refinancings (Ashford $580M debt elimination). Strategic alternatives (ENDRA, Ashford) and mergers (First Foundation/FirstSun closing Apr 1, 2026) signal potential M&A catalysts, while ETF leadership changes at iShares/21Shares indicate crypto/alt asset stabilization. Hospitality/retail outliers like Ashford (+40bps margins, +2.4% EBITDA) and Ross (+5% comp sales) outperform peers amid sector headwinds, positioning for Q2 2026 catalysts like AGMs and revenue thresholds.

40 high priority10 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 31, 2026

Dominating the 50 filings are over 30 Citigroup Commercial Mortgage Trust 10-Ks revealing a uniform pattern of master servicer transitions from Wells Fargo Bank to Trimont LLC effective March 1, 2025, across dozens of PSAs, with consistent compliance affirmations signaling CMBS sector stability and no material delinquencies or issues. Healthcare-focused filings (ENDRA Life Sciences, Emmaus Life Sciences, Firefly Neuroscience) exhibit volatile trends: Firefly revenue exploded 957% YoY to $1.14M but losses widened to $19.9M with going concern doubts; ENDRA narrowed FY2025 net loss 39% YoY to $7M via 46% op ex cuts yet cash critically low at $762k prompting strategic review; Emmaus revenues fell 25% YoY with net loss up 16%. Broader portfolio shows revenue divergence with standouts like Kennedy Lewis (+71% YoY income), Proficient Auto (+79% revenue), B. Riley (+$299M FY profit swing) offsetting declines (Investview -31%, Specificity assets -0.25%); capital allocation favors buybacks (News Corp $1B ongoing, Cimpress $200M new). Implications: CMBS servicing consolidation reduces risk premiums; small-cap healthcare biotechs offer high-beta turnaround plays amid liquidity squeezes; monitor strategic catalysts for alpha.

42 high priority8 medium50 total filings

🇺🇸United States·March 31, 2026·daily

US Executive Compensation Proxy SEC Filings — March 31, 2026

Across 50 DEF 14A proxy statements filed around March 31, 2026, companies predominantly highlight strong 2025 performance with disclosed revenue growth averaging +11% YoY (e.g., Range Resources +11%, Wabtec +7.5%, nVent +30%, SPX +14.2%), margin expansions (Ashford +40 bps Hotel EBITDA), and robust capital returns exceeding $10B in aggregate dividends and buybacks (e.g., Marsh & McLennan $3.7B, Akamai $800M repurchases, Range $317M total). Positive sentiment prevails in 14 filings (28%), mixed in 8 (16%), with neutral in the rest; high-materiality (8-9/10) names show portfolio-level trends of deleveraging (e.g., Range net debt -186M, Essential 3.8x leverage), asset sales/strategic shifts (SITE $847.8M sales), and M&A (Transocean/Valaris). Executive compensation is largely performance-tied with above-target payouts (Merit 124.53% of target vs 118.90% 2024), though TSR lags in some (Marsh -11.3% vs S&P). Upcoming May 2026 annual meetings cluster as catalysts for say-on-pay votes (all recommend FOR), board elections, and auditor ratifications, implying low controversy but watch for shareholder proposals. Market implications favor industrials/REITs/utilities with growth+returns; energy/transport outliers signal caution amid headwinds.

50 high priority50 total filings

🇺🇸United States·March 31, 2026·daily

US IPO Pipeline SEC S-1 Filings — March 31, 2026

The March 31, 2026, IPO Pipeline stream reveals three S-1/S-4 filings dominated by pre-IPO preparations and merger activity, with neutral sentiment across all (Bitcoin Depot, VYNE Therapeutics, Churchill Capital Corp X). Overarching themes include aggressive share restructuring via reverse splits in 2/3 filings (Bitcoin Depot's 1-for-7 on Feb 23, 2026, reducing Class A shares 85.7% from 35.5M to 5.1M and Class M 85.7% from 37.8M to 5.4M; VYNE's potential post-merger split), signaling efforts to boost per-share metrics for listing compliance amid no disclosed financial trends. Churchill stands out as post-IPO SPAC (41.4M units sold May 15, 2025, full over-allotment exercised, no Founder Share forfeitures), targeting quantum tech via Infleqtion with Sponsor holding 10.35M cheap Founder Shares (initial $0.003/share). No period-over-period financials provided, but capital events like splits and low-cost equity issuance highlight capital allocation focus on dilution control. Market implications point to crypto/biotech/quantum sectors prepping for public markets, with reverse splits as potential distress flags but merger/SPAC paths offering de-SPAC catalysts. Portfolio-level pattern: 100% of filings involve restructuring (splits, conversions, capitalizations), prioritizing Nasdaq compliance over growth narratives.

3 high priority3 total filings

🇺🇸United States·March 31, 2026·daily

Global High-Priority Regulatory Events — March 31, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include distress signals in Indian firms (closures, defaults, insolvencies in EID Parry, MT Educare, AGS Transact), mixed US small-cap financials with revenue declines offset by cost controls (e.g., Investview -31% YoY revenue but -12% expenses), and positive M&A/catalyst momentum in biotech/energy (SCYNEXIS acquisition, T1 Energy record production). Period-over-period trends show 8/20 10-K filers with revenue declines averaging -25% YoY (e.g., CKX Lands -45%, HireQuest -11%), but 6/20 improved net losses via impairments/cost cuts; energy outliers like Range Resources +11% sales YoY contrast broader weakness. Capital allocation leans shareholder-friendly in survivors (Marsh $2B buybacks, Range $231M repurchases/$86M dividends), while SPACs/M&A amendments signal delayed but resilient dealmaking (Soulpower $8.5B valuation). RBI amendments tighten acquisition/bridge finance norms, potentially curbing M&A; mortgage trusts highlight routine servicer transitions (Wells Fargo to Trimont March 2025). Portfolio implications: overweight US energy/biotech catalysts, underweight Indian distress names, monitor SPAC closings for Q2/Q3 2026 alpha.

50 high priority50 total filings

🇺🇸United States·March 31, 2026·daily

US Earnings Financial Results SEC Filings — March 31, 2026

Across 50 10-K filings for FY2025 (ended Dec 31, 2025), mixed sentiment dominates with 14/50 explicitly mixed, reflecting turnarounds in select operating companies (e.g., TruBridge net income from -$21M to +$4M, HireQuest +72% net income) amid widespread losses in biotechs/pharma (avg loss expansion +100% YoY in Athira, Sharps, OS Therapies). Revenue trends show resilience in retail (Ross Stores +8% YoY to $22.8B, FitLife +26%) but declines in resources (CKX Lands -45%, SD Soy -9%) and flatlines in tech/services (KORE 0%, TruBridge +1%); operational cash flow improved in 6/15 detailed cos (e.g., Ross +28% to $3B). CMBS trusts (16/50) uniformly neutral with recurring master servicer transitions to Trimont LLC effective Mar 1, 2025, signaling standardization but no delinquencies flagged. SPACs/funds (10/50) hold robust trust assets (e.g., Berto $309M, Invest Green $173M) with low materiality risks pre-combination. Biotech cash burn persists (OS Therapies cash -95% to $270k) offset by financings (Athira PIPE $82M net); capital allocation favors equity raises over dividends/buybacks. Portfolio implication: Favor retail turnaround plays, monitor CMBS servicer shifts for liquidity hints, avoid high-burn biotechs without catalysts.

50 high priority50 total filings